| Filed On | Filing |
|---|---|
| 13 Nov 2026 | REGISTRATION STATEMENT |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
AT177 IND submission and Phase 1a initiation on track for the first half of 2027 |
| 12 Nov 2026 | QUARTERLY REPORT |
| 10 Nov 2026 |
Form 3: Soloway Thomas M, Director
No securities owned |
| 10 Nov 2026 |
Form 3: Hastings Paul J, Director
No securities owned |
| 10 Nov 2026 |
Form 3: Habtezion Aida, Director
No securities owned |
| 09 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On November 3, 2026, each of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appointed to the Board of Directors (the “Board”) of Azora Therapeutics, Inc. (formerly known as Adial Pharmaceuticals, Inc.) (the “Company”). Dr. H... |
| 04 Nov 2026 |
Form 4: Davidson Matt, Director
Received 626,252 shares by conversion |
| 04 Nov 2026 |
Form 4: Saiki Julie, Chief Strategy Officer
Received 626,252 shares by conversion |
| 03 Nov 2026 |
Form 4: Coastlands Capital Lp, 10% owner
Holds 388,308 shares of Common Stock |
| 03 Nov 2026 | SCHEDULE 13G/A |
| 30 Oct 2026 |
Form 4: Davidson Matt, Director
Received 232,417 shares as a grant or award · Granted 1,923.428 Series A Preferred Stock · Granted 884,205 Stock Option (Right to Buy) |
| 30 Oct 2026 |
Form 3: Saiki Julie, Chief Strategy Officer
Holds 72,719 shares of Common Stock |
| 30 Oct 2026 | Form 3: Economides Vassiliki, Chief Financial Officer |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis |
| 26 Oct 2026 | EFFECT |
| 21 Oct 2026 | AMENDMENT NO. 1 TO FORM 10-Q |
| 21 Oct 2026 | AMENDMENT NO. 1 TO FORM S-3 |
| 16 Oct 2026 | DEFINITIVE ADDITIONAL MATERIALS |
| 16 Oct 2026 |
8-K: Other Events
As previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 18, 2026, on September 17, 2026, the Company convened it... |
Loading...